Endovia Health Sciences entered into a Letter Agreement with C/M Capital Master Fund to invest a minimum of $1 million for the regulatory and commercial development of CannEpil. The company closed an initial investment of $510,000 in exchange for a secured convertible promissory note with a principal amount of $576,271. This debt instrument converts into common stock at the lower of $1.75 or $0.01 above the closing price and matures on September 18, 2027. Additionally, the company issued 3,629,250 shares under an existing equity line of credit for gross proceeds of $808,829.42 between August 31 and September 23, 2026. Endovia Health Sciences operates in the pharmaceutical industry, focusing on the development and commercialization of medical treatments.
